Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Assertio Therapeutics ( (ASRT) ) just unveiled an update.
On May 7, 2026, Assertio Holdings and Garda Therapeutics mutually agreed to extend the deadline to commence Garda’s tender offer to acquire all outstanding shares of Assertio’s common stock to May 14, 2026. The move temporarily shifts the timing of Garda’s planned $21.80-per-share all-cash acquisition of Assertio, valued at approximately $153.2 million, and aligns the launch of Garda’s stock tender offer and Assertio’s tender offer for its outstanding Convertible Senior Notes with the company’s planned filing of its Schedule 14D-9 on the same date.
The synchronized May 14, 2026 timing is intended to provide a clearer framework for Assertio shareholders and noteholders ahead of a potential change of control. For stakeholders, the delay underscores that the deal remains on track while giving the parties additional time to finalize documentation and regulatory filings, a step that may reduce execution risk but extends near-term uncertainty around the closing of the transaction and Assertio’s future as a Garda subsidiary.
The most recent analyst rating on (ASRT) stock is a Hold with a $21.80 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.
Spark’s Take on ASRT Stock
According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.
The score is held back primarily by weak financial performance (multi-year revenue declines, ongoing losses, and 2025 cash flow turning negative). Offsetting this are strong technical momentum and a significant positive corporate catalyst from the enhanced all-cash acquisition agreement, while valuation remains difficult to support due to negative earnings.
To see Spark’s full report on ASRT stock, click here.
More about Assertio Therapeutics
Assertio Holdings is a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’ needs. The company focuses on supporting patients by marketing therapeutics primarily in the oncology market, positioning itself within specialty pharma targeting cancer-related indications.
Average Trading Volume: 215,856
Technical Sentiment Signal: Hold
Current Market Cap: $144.2M
See more data about ASRT stock on TipRanks’ Stock Analysis page.